Martek fire fallout
This article was originally published in The Tan Sheet
Executive Summary
Fire at supplier DSM's Belvidere, N.J. ARA manufacturing plant will cause an estimated $5 mil. to $10 mil. loss in sales this quarter, Martek estimates in a May 17 statement. The fire shut down ARA production, which could be discontinued at the facility for a period of weeks. The full impact on the firm's revenues "will be determined once the extent of equipment damage is further assessed." Separately, Martek announced the filing of a universal SEC-shelf registration statement May 21 for debt securities, stock and warrants with a value of up to $200 mil...
You may also be interested in...
Glaxo Mother’s goes subcontinental
GlaxoSmithKline launches Mother's Horlicks in India, a powdered drink mix for pregnant and breast-feeding mothers containing Martek's docosahexaenoic acid (DHA), Martek announces June 24. Mother's Horlicks is a "small part" of the Horlicks line, but Martek believes the product "will help set the stage" for expanded food and beverage applications for other products containing DHA. Martek recorded revenues of $41.9 mil. with earnings of $3.4 mil. in its most recent quarter, with results reflecting inefficiencies in the firm's arachidonic acid (ARA) production and a loss of sales due to a fire at a N.J. manufacturing facility (1"The Tan Sheet" May 24, 2004, In Brief)...
Alvotech And Cipla Expand Biosimilars Deal For Australia And New Zealand
Cipla has expanded its partnership with Alvotech to cover the commercialization of five biosimilars in Australia and New Zealand, building on an existing alliance covering South Africa and emerging markets.
No Eudamed, No Problem! Latest Guidance Explains Alternatives While Database Is Built
Lack of official explanation about how the exchange of critical information will progress pending the launch of the EU’s medical device database, Eudamed3, has left many confused. New guidance lights the way forward.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: